The Medical management of cushing's syndrome

Alfonso Leal-Cerro, Alfonso Soto Moreno, Miguel Angel Mangas, Antonio León Justel, Susan Webb

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

4 Cites (Scopus)


Cushing's syndrome results from prolonged exposure to excessive circulating glucocorticosteroids and is associated with significant morbidity and mortality. While the treatment of choice in most patients is surgical, the metabolic consequences of this syndrome, including hypertension and diabetes mellitus, increase the risks of such surgery. Hypercortisolemia and its sequelae can be efficiently reversed or controlled using medical therapy, either as a temporary measure prior to definitive treatment or as a longer-term treatment in some particularly difficult cases. Drug treatment has been targeted at the hypothalamic/pituitary level, the adrenal glands and at glucocorticoid receptors. The present review discusses the pharmacotherapeutic agents that have been used in Cushing's syndrome and the criteria for their use, as well as recent drugs that may improve the medical treatment of this complex endocrinological disorder in the future. Finally, the shortand long-term follow-up of patients with Cushing's syndrome after surgery is also discussed. © 2009 Sociedad Española de Endocrinología y Nutrición.
Idioma originalEnglish
Pàgines (de-a)187-194
RevistaEndocrinologia y Nutricion
Estat de la publicacióPublicada - 1 d’abr. 2009


Navegar pels temes de recerca de 'The Medical management of cushing's syndrome'. Junts formen un fingerprint únic.

Com citar-ho